When was Syntax Bio founded?

Syntax Bio was founded in 2018.

Where is Syntax Bio located?

Syntax Bio is headquartered in Chicago, United States.

Is Syntax Bio a funded company?

Syntax Bio is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Syntax Bio rank among its competitors?

Syntax Bio ranks 12th amongst 85 active competitors, of which 12 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Genoskin, which secured $5.4M in Sep, 2025.

Who are the top competitors of Syntax Bio?

Syntax Bio's top competitors include Magnitude Biosciences, Genoskin and Reaction Biology. Among them, Genoskin secured the most recent funding round in September, 2025.

Syntax Bio - 2026 Company Profile & Competitors

Company Details

Syntax Bio is a preclinical-stage biotechnology company focused on advancing stem cell-derived therapies. The company utilizes a modified CRISPR system to direct stem cells to become a desired cell type, enhancing scalability and efficiency in cell therapy manufacturing. With its innovative technology platform, Syntax Bio aims to overcome longstanding challenges in stem cell-derived therapies and unlock new possibilities for treating various diseases.

Key Metrics

Founded Year

2018

Location

Chicago, United States

Stage

Unfunded

Ranked

12^th among 85 active competitors

Similar Companies

Magnitude Biosciences & 94 more

View Syntax Bio's full profile

Syntax Bio has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Syntax Bio include Magnitude Biosciences, Genoskin and Reaction Biology. Here is the list of Top 10 competitors of Syntax Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Magnitude Biosciences 2018, Durham (United Kingdom), Seed	Provider of cell-free in vitro assay for drug discovery companies	$2.6M	Northstar Ventures, Saker Capital & 10 others	58/100
2nd	Genoskin 2011, Toulouse (France), Series A	In vitro human skin models for preclinical toxicity and efficacy testing	$5.4M	OCCTE, Caisse D Epargne & 7 others	53/100
3rd	Reaction Biology 2001, United States, Late Stage	In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling	-	Cobepa, CYwP Funds & 7 others	45/100
4th	ACE Research 2016, Kisumu (Kenya), Unfunded	Provider of contract research organization services for clinical trials	-	-	43/100
5th	Discovery Biomed 2007, Birmingham (United Kingdom), Acquired	Contract research organization	-	NIH, NIDDK & 4 others	39/100
6th	Quantumcyte 2013, Sunnyvale (United States), Seed	Drug assay system to treat cancer	$1.3M	IndieBio, Bayes Ventures	39/100
7th	Radiant Research Services 2009, Bengaluru (India), Acquired	Preclinical in vitro testing and development services	-	-	36/100
8th	Leadgene Biomedical 2013, Tainan (Taiwan), Unfunded	CRO offers invitro drug testing services	-	-	35/100
9th	Orient Gene Biotech 2005, China, Unfunded	Manufactrurer and R&D of in vitro diagnostic reagents	-	-	35/100
10th	American Preclinical 2005, Minneapolis (United States), Acquired	Provider of preclinical services specializing in medical devices and pharmaceuticals	-	-	34/100
12th	Syntax Bio 2018, Chicago (United States), Unfunded	Preclinical-stage biotech company that develops innovative stem cell-derived therapies by leveraging CRISPR technology	-	-	33/100